Business Segments · Sales
Biotechnology — Sales
Danaher Biotechnology — Sales decreased by 69.8% to $1.8B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 68.7%, from $5.74B to $1.8B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2017
Last reportedQ1 2026Apr 21, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market share or demand, while a decrease suggests competitive pressure or market contraction.
Detailed definition
Represents the total revenue generated from the sale of products and services within the biotechnology business segment....
Peer comparison
Standard revenue reporting across life science and diagnostic peers.
Metric ID:
dhr_segment_biotechnology_salesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.22B | $2.14B | $7.23B | $2.14B | $3.5B | $2.14B | $6.53B | $2.22B | $6.53B | $2.27B | $6.46B | $2.05B | $7.13B | $2.22B | $5.95B | $1.86B | $5.91B | $1.89B | $5.62B | $1.66B | $6.41B | $1.76B | $5.8B | $1.52B | $5.74B | $1.71B | $5.8B | $1.65B | $6.54B | $1.87B | $5.74B | $1.61B | $5.94B | $1.85B | $6.05B | $1.8B | $6.84B | $2.03B | $5.95B | $1.8B |
| QoQ Change | — | -70.3% | +237.4% | -70.4% | +63.2% | -38.7% | +204.6% | -66.0% | +194.6% | -65.3% | +184.9% | -68.2% | +247.5% | -68.8% | +167.6% | -68.7% | +217.2% | -68.1% | +198.4% | -70.4% | +284.9% | -72.5% | +229.5% | -73.7% | +276.8% | -70.2% | +238.5% | -71.5% | +295.5% | -71.4% | +207.2% | -71.9% | +268.2% | -68.8% | +227.2% | -70.3% | +280.3% | -70.3% | +192.7% | -69.8% |
| YoY Change | — | — | — | — | — | — | — | — | -9.6% | -68.6% | -10.7% | -71.6% | +104.0% | -36.4% | -8.8% | -71.4% | -9.4% | -71.1% | -12.9% | -74.2% | -10.2% | -75.3% | -2.6% | -74.4% | -2.9% | -71.0% | +3.1% | -70.6% | +2.1% | -70.8% | -0.9% | -72.2% | +3.4% | -67.8% | +4.4% | -69.0% | +4.6% | -68.9% | +3.7% | -68.7% |
Range$1.52B – $7.23B
CAGR-13.3%
Avg YoY Growth-32.7%
Median YoY Growth-24.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology — sales?
- Danaher (DHR) reported biotechnology — sales of $1.8B in Q1 2026.
- How has Danaher's biotechnology — sales changed year-over-year?
- Danaher's biotechnology — sales decreased by 68.7% year-over-year, from $5.74B to $1.8B.
- What does biotechnology — sales mean?
- Total revenue generated by the biotechnology business segment.